

## Director's Dealings

### *PuriCore Director Acquires Shares in the Company*

**MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 21 June 2010** — [PuriCore](#) (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces today announces that on 18 June 2010 the following Director has purchased shares in the Company as set out below:

| <b>Director Name</b> | <b>Number of shares purchased</b> | <b>Purchase Price of shares</b> | <b>Total number of shares held</b> | <b>% of issued share capital</b> |
|----------------------|-----------------------------------|---------------------------------|------------------------------------|----------------------------------|
| Darren Weiss         | 15000                             | 10.14p                          | 15000                              | 0.01%                            |

#### **Enquiries:**

|                      |                   |
|----------------------|-------------------|
| Ben Brewerton        | Greg Bosch, CEO   |
| Susan Quigley        | Darren Weiss, CFO |
| Financial Dynamics   | PuriCore          |
| +44 (0) 20 7831 3113 | +1 484 321 2700   |

#### **About PuriCore**

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of *C.difficile*, *E.coli*, HIV, Human and Animal Influenza (including H1N1 and H5N1), *Legionella*, *MRSA*, *M.tuberculosis*, Norovirus, and *Salmonella*. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at [www.puricore.com](http://www.puricore.com), which does not form part of this press release.